
Hester Biosciences Ltd is Rated Sell
2026-11-21 10:10:47Hester Biosciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 11 November 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 November 2026, providing investors with the most up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read More
Hester Biosciences Ltd is Rated Hold by MarketsMOJO
2026-11-10 10:10:16Hester Biosciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 06 Nov 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 10 November 2026, providing investors with the latest insights into its performance and outlook.
Read MoreHester Biosciences Gains 2.25%: 2 Key Factors Driving the Week’s Mixed Momentum
2026-11-08 09:01:09Key Events This Week 2 Nov: Stock opens at Rs.2,270.35, declines 1.28% 4 Nov: Strong rebound with 2.57% gain to Rs.2,318.85 5 Nov: Sharp 4.34% rise to Rs.2,419.55 on positive quarterly outlook 6 Nov: Promoter exit announcement coincides with 2.81% drop to Rs.2,351.55 Week OpenRs.2,299.80 Week Close<div class="stat-val...
Read More
Hester Biosciences Ltd Reports Strong Quarterly Growth Amid Positive Financial Trend
2026-11-06 11:00:25Hester Biosciences Ltd has demonstrated a marked improvement in its financial performance for the quarter ended September 2026, signalling a positive shift from a previously flat trend. The company’s revenue growth, profitability, and operational efficiency have all shown significant gains, although certain cost pressures remain a concern. This analysis delves into the recent quarterly results, compares them with historical trends, and assesses the implications for investors amid a challenging market backdrop.
Read More
Hester Biosciences Ltd is Rated Sell
2026-10-30 10:10:24Hester Biosciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 October 2026, providing investors with an up-to-date view of the company's fundamentals, valuation, financial trends, and technical outlook.
Read More
Hester Biosciences Ltd is Rated Sell
2026-10-19 10:10:22Hester Biosciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 October 2026, providing investors with the latest insights into the company’s performance and outlook.
Read More
Hester Biosciences Ltd is Rated Sell
2026-10-08 10:10:47Hester Biosciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 October 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.
Read More
Hester Biosciences Ltd is Rated Sell
2026-09-27 10:10:16Hester Biosciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 July 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 27 September 2026, providing investors with the latest insights into its fundamentals, valuation, financial trends, and technical outlook.
Read More
Hester Biosciences Ltd is Rated Sell
2026-09-16 10:10:36Hester Biosciences Ltd is rated Sell by MarketsMOJO. This rating was last updated on 30 July 2026, reflecting a reassessment of the company’s outlook. However, the analysis and financial metrics presented here are based on the stock’s current position as of 16 September 2026, providing investors with the latest insights into its performance and valuation.
Read MoreAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
07-Nov-2026 | Source : BSE20261105 Transcript of Earnings Conference Call for Q2 & H1 FY27 Financial Results
Announcement under Regulation 30 (LODR)-Newspaper Publication
06-Nov-2026 | Source : BSE20261106 Newpaper Clippings of Financial Results
Announcement Under Regulation 30 Of Listing Regulations - Approved An Unsecured Loan To Foreign Wholly-Owned Subsidiary
05-Nov-2026 | Source : BSEDisclosure under regulation 30 of Listing Regulations - Board of Directors approved an unsecured loan to Hester Biosciences Africa Limited Foreign wholly-owned subsidiary of the Company.
Corporate Actions
No Upcoming Board Meetings
Hester Biosciences Ltd has declared 110% dividend, ex-date: 14 Jul 26
No Splits history available
Hester Biosciences Ltd has announced 1:2 bonus issue, ex-date: 27 Sep 12
Hester Biosciences Ltd has announced 2:5 rights issue, ex-date: 29 May 06